© 1998 American Heart Association, Inc.
Original Contributions |
Combination of Fosinopril and Pravastatin Decreases Platelet Response to Thrombin Receptor Agonist in Monkeys
From the Department of Medicine, Wake Forest University School of Medicine (L.P.H., K.T.C.), and the Department of Pathology, Wake Forest University Baptist Medical Center (A.M.B.), Winston-Salem, NC; Clinical Pathology Consultants, Conway, SC (M.V.S.); and the Departments of Public Health Sciences (L.D.C.) and Medicine (J.O.), Wake Forest University School of Medicine, Winston-Salem, NC.
Correspondence to L. Paulette Hale, MD, Hematology/Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, First Floor, Watlington Hall, Winston-Salem, NC 27157. E-mail phaleobi{at}earthlink.net
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Abstract—Both angiotensin-converting enzyme (ACE) inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors have been shown to decrease cardiovascular morbidity and mortality. Results from clinical trials have suggested that HMG-CoA reductase inhibition might exert a beneficial effect independent of its lipid-lowering effect, and ACE inhibition may exert a benefit independent of blood-pressure lowering. To test the hypothesis that such an effect might be mediated by alteration in platelet reactivity, we studied 55 monkeys receiving both, 1, or neither of the ACE inhibitor fosinopril and the HMG-CoA reductase inhibitor pravastatin. Platelet responsiveness to collagen and to the thrombin receptor agonist (TRA) SFLRRN-NH2 was determined by aggregometry. For each agonist, the maximum rate and extent of aggregation were measured for each dose, and the concentration required for half-maximal response (C50) was determined. Each drug, when given alone, slightly decreased the dose of agonist required to produce 50% response in the rate and extent of platelet aggregation relative to control. The combination of the 2 drugs, however, produced a significant increase in the dose of TRA required to produce 50% response in the rate and extent of aggregation relative to either drug alone or the control group. This was not true for collagen. The magnitude of the change relative to the control group, 47% for rate and 30% for extent of aggregation, could confer considerable protection by changing the threshold for thrombin-induced platelet aggregation and, thus, decrease thrombosis.
Key Words: angiotensin-converting enzyme inhibitors • platelet aggregation • 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Cardiovascular disease is the leading cause of death in the United States.1 Most of the morbidity and mortality of this disease results from the rupture of atherosclerotic plaques in the vessel wall. This event leads to exposure of the thrombogenic inner components of the plaque to circulating blood, resulting in platelet activation and aggregation and activation of the coagulation system. Subsequently, a thrombus forms.2 The use of angiotensin-converting enzyme (ACE) inhibitors and lipid-lowering drugs has decreased cardiovascular morbidity and mortality below that expected from the resulting mild reduction in blood pressure and minor reduction in severity of coronary stenosis.2 3 4 Therefore, in addition to their well-known actions, these drugs probably have other protective effects on the processes that lead to cardiovascular disease and thrombosis. It is possible that these drugs may affect platelet function.
In this randomized trial, we studied platelet responsiveness to collagen and a thrombin receptor agonist (TRA) in monkeys that were treated with an ACE inhibitor, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, both drugs, or neither drug.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Materials
The highly purified peptide TRA SFLRRN-NH2 (PMIS387) was purchased from BACHEM California; type I collagen was purchased from Chronolog.
Animals
This research was a randomized, therapeutic study of syngeneic,
atherogenesis-prone monkeys (Macaca fascicularis)
that initially included 63 individuals; however, 8 were not evaluable
because they expired from unrelated causes. The monkeys were treated
for 2 years and fed a nutritionally complete,
low-cholesterol diet. The monkeys were sedated with
ketamine before venipuncture. Blood was drawn by
venipuncture from the left femoral vein into 3.8% sodium
citrate. This institution's animal use and care committee reviewed and
approved the study.
Platelet Preparation
Platelet-rich plasma was prepared by
centrifugation of the blood at 900 rpm for 15
minutes at 20°C. Platelet counts were adjusted with
platelet-poor plasma from the same monkey to 200 000 to
300 000/µL.
Platelet Aggregation
Platelet aggregation studies were performed by using
standard techniques without knowledge of the specific monkey
group.5 Each platelet-rich plasma was
incubated at 37°C for 2 minutes and stirred for 1 minute at 1100 rpm
in an aggregometer (PAP 4-C, Biodata). Platelets were then
stimulated with a range of concentrations of the TRA (5 to 1000
µmol/L) and collagen (0.4 to 1000 µg/mL), and the optical
density was recorded for 4 minutes. Serial dilutions of the
agonists were tested to span the range of full aggregation to zero
aggregation. For each dose of agonist used, the maximum rate and extent
of aggregation were measured.
Interpretation
A logistic dose-response curve was fitted to the response data
for each agonist with each monkey and was used to determine the
relationships between aggregation response and agonist dose. An example
of a typical dose-response curve is shown in the
Figure
. The fitted curves allowed the
determination of the agonist concentration required to produce
half-maximal response (C50).
|
Statistical Methods
Four outcome measures are considered in this report, namely, the
concentration of agonist required to produce half-maximal (ie,
C50) rate and extent of platelet aggregation
after stimulation with either the TRA or collagen. Means and SDs for
these measures were calculated separately for each treatment arm. Each
outcome measure was analyzed by ANOVA. Rank transformations
were used owing to some outliers and heteroscedasticity. Initial models
included terms for each treatment and their interaction. When
interactions were nonsignificant, only main effects were fitted in the
models. When interactions were significant, pairwise contrasts were
tested to assess differences among the 4 groups. Four other measures,
systolic and diastolic blood pressure, total plasma
cholesterol, and intimal area, were also assessed in this
study. The first 3 were analyzed by 2-way ANCOVA after
adjustment for baseline values. Intimal area was assessed by ANCOVA
after adjustment for baseline LDL plus VLDL and HDL
cholesterol. Logarithmic transformations were used where
necessary to normalize the data. Interactions for these 4
analyses were performed as previously described. Reported
P values were unadjusted for multiple comparisons, and
values of P<0.05 were considered statistically
significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Sixty-three monkeys were randomized into 4 groups. A total of 8 animals were not evaluable because they expired from unrelated causes, leaving 55 evaluable monkeys. Twelve of these were treated with 10 mg/kg body weight per day of an HMG-CoA reductase inhibitor (pravastatin); 11 received 20 mg/kg body weight per day of an ACE inhibitor (fosinopril); 16 received both drugs daily; and 16 were left untreated. The means and SDs of the C50 for each agonist used in each monkey group are listed in the Table
.
|
TRA Stimulation
ANOVA revealed a significant interaction between
pravastatin and fosinopril for C50s
for both extent (P=0.0221) and rate (P=0.0321) of
platelet aggregation. Pairwise contrasts among the 4 groups were
then tested to assess treatment differences. For those monkeys not
receiving pravastatin, the addition of fosinopril slightly,
but nonsignificantly, decreased the C50 for both
the extent (1.01 versus 0.79, P=0.3290) and rate (0.84
versus 0.71, P=0.5081) of aggregation. However, for those
monkeys receiving pravastatin, the addition of fosinopril
significantly increased the C50 for both the
extent (0.92 versus 1.31, P=0.0210) and the rate (0.82
versus 1.23, P=0.0162) of aggregation.
Similarly, for those monkeys not receiving fosinopril, the addition of pravastatin had little effect on the C50 for either the extent (1.01 versus 0.92, P=0.7386) or rate (0.84 versus 0.82, P=0.9409) of aggregation. However, for those monkeys receiving fosinopril, the addition of pravastatin significantly increased the C50 for both the extent (0.79 versus 1.31, P=0.0043) and rate (0.71 versus 1.23, P=0.0026) of aggregation.
Collagen Stimulation
In this setting, the interaction between fosinopril and
pravastatin was nonsignificant for the
C50s for extent (P=0.6997) and rate
(P=0.9024) of aggregation. In addition, neither fosinopril
nor pravastatin significantly affected the
C50 for either extent or rate of aggregation. The
mean C50 for extent was 0.172 and 0.188 for
monkeys that did and did not receive pravastatin,
respectively (P=0.7968). The mean C50
for rate was 0.175 and 0.210, respectively (P=0.7632). The
mean C50 for extent was 0.149 and 0.209 for
monkeys that did and did not receive fosinopril, respectively
(P=0.7468). The mean respective C50
for rate was 0.159 and 0.224 (P=0.7800).
Neither fosinopril nor pravastatin, alone or in combination, had a significant effect on systolic blood pressure or total cholesterol. Interestingly, however, the monkeys that received both drugs had a significantly lower diastolic blood pressure than did those that received neither drug or either drug alone. The adjusted mean diastolic blood pressure for the group receiving both drugs was 40.4, compared with 52.3 for the group receiving neither drug (P=0.0014), 50.9 for the group receiving fosinopril alone (P=0.0087), and 53.2 for the group receiving pravastatin alone (P=0.0012). In addition, there was no significant difference in the intimal area of the coronary arteries among monkey groups, which suggests that there was no significant alteration in atherosclerosis.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Conflicting results have been published regarding the effect of ACE inhibitors on platelet function. Patients on captopril therapy had decreased platelet aggregation in response to ADP, epinephrine, collagen, and arachidonic acid6 ; however, platelet aggregation induced by epinephrine, ADP, and collagen in patients on quinapril therapy and by ADP and arachidonic acid in patients on lisinopril therapy was unchanged.7 8 Recently, the effect of fosinopril on platelet aggregation was evaluated by using collagen and ADP in hypertensive patients. ADP-induced platelet aggregation decreased by 31% after treatment with fosinopril, whereas collagen response was unchanged.9
Platelet aggregability has been shown to decrease with decreasing levels of LDL in patients with familial hyperlipidemia and in normolipidemic males.10 11 HMG-CoA reductase inhibitors, such as lovastatin and pravastatin, lower LDL cholesterol,12 13 which should result in decreased platelet sensitivity to aggregation. However, the actual effect of HMG-CoA reductase inhibitors on platelets is unclear. One study showed an increase in platelet sensitivity to ADP in patients treated with lovastatin for 26 weeks, despite a significant decrease in their LDL cholesterol levels.12 In contrast, another study evaluated platelet aggregation in patients treated with lovastatin for 1 year and found a significant decrease in ADP-induced platelet aggregation.14
We studied platelet function by using collagen and TRA in all 4 monkey groups. Because it was not possible to obtain large quantities of platelet-rich plasma, we chose to study only these 2 agonists but in detail. By using a wide range of concentrations of each agonist, we were able to determine the dose-response curves and C50s for each agonist, thus producing quantitative results of platelet function. In our study, a significant difference in platelet responsiveness was not seen with either drug alone; however, the combination of the 2 drugs resulted in a significant increase in the dose of TRA required to produce a 50% response in both the rate and extent of aggregation compared with either drug alone or with controls. No significant change was observed in response to collagen, possibly indicating a selective effect. It is not possible to know whether these effects are drug- or class-specific; however, this is a very interesting question that needs to be studied. It is quite intriguing that the difference in aggregation was present even though there was no significant change in systolic blood pressure, total plasma cholesterol, or intimal area of the coronary arteries and that the significant change in diastolic blood pressure occurred only in the group receiving both drugs. These observations suggest that the platelet effect may be independent of the well-known effects of these 2 drugs.
This study was a randomized trial in animals, and the results may not extrapolate to humans. However, a trial such as this provides a good starting point for preliminary data. Animal studies, when compared with human studies, have very definite advantages that stem from a tightly controlled study environment: the animals are syngeneic, are fed the same diet, and are not on other medications that might interfere with the aggregation results or study drugs; the dropout rate is low; and noncompliance is not an issue.
Previous trials evaluating platelet function in patients on ACE inhibitors and HMG-CoA reductase inhibitors have yielded conflicting results. In our study, although platelet function was not significantly affected by either drug alone, the combination resulted in a surprising decrease in platelet sensitivity to the TRA. Response to collagen was not significantly affected. One must consider that the combination of these drugs is somehow affecting the thrombin receptor, because the response to collagen was unaffected. Several possible explanations for these results come to mind: drug alteration of the thrombin receptor leading to decreased sensitivity of the receptor; direct interference with the receptor by the drugs; a decrease in the number of receptors; and a decrease in the recycling of the receptors. These results lead one to ponder whether affects on platelets may also contribute to the decreased cardiovascular morbidity and mortality that is associated with treatment with ACE inhibitors and HMG-CoA reductase inhibitors.
|
Acknowledgments |
|---|
This research was supported in part by grant CA-12197 from the National Cancer Institute (J.O.) and an unrestricted grant from Bristol-Myers Squibb (J.O.). We would like to thank Thomas B. Clarkson, DVM, Department of Comparative Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, for his invaluable contribution to our study.
Received September 30, 1997; accepted April 8, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Flack JM, Yunis C. Therapeutic implications of the epidemiology and timing of myocardial infarction and other cardiovascular diseases. J Hum Hypertens. 1997;11:23–28.[Medline] [Order article via Infotrieve]
2. Shah PK. Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin. 1996;14:17–29.[Medline] [Order article via Infotrieve]
3. Pitt B. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia. Am J Cardiol. 1997;79:24–28.
4. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol. 1996;27:1048–1052.[Abstract]
5. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol. 1963;168:178–195.
6. Someya N, Morotomi Y, Kodama K, Kida O, Higa T, Kondo K, Tanaka K. Suppressive effect of captopril on platelet aggregation in essential hypertension. J Cardiovasc Pharmacol. 1984;6:840–843.[Medline] [Order article via Infotrieve]
7. Gupta RK, Kjeldsen SE, Motley E, Weder AB, Zweifler AJ, Julius S. Platelet function during antihypertensive treatment with quinapril, a novel angiotensin converting enzyme inhibitor. J Cardiovasc Pharmacol. 1991;17:13–19.[Medline] [Order article via Infotrieve]
8. Zannad F, Bray-Desboscs L, el Ghawi R, Donner M, Thibout E, Stoltz, JF. Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated double-blind study. J Hypertens. 1993;11:559–564.[Medline] [Order article via Infotrieve]
9. Keidar S, Oiknine J, Leiba A, Shapira C, Leiba M, Aviram M. Fosinopril reduces ADP-induced platelet aggregation in hypertensive patients. J Cardiovasc Pharmacol. 1996;27:183–186.[Medline] [Order article via Infotrieve]
10. Brook G, Winterstein G, Aviram M. Platelet function and lipoprotein levels after plasma-exchange in patients with familial hypercholesterolaemia. Clin Sci. 1983;64:637–642.[Medline] [Order article via Infotrieve]
11.
Hassall DG, Forrest LA, Bruckdorfer KR, Marenah CB,
Turner P, Cortese C, Miller NE, Lewis B. Influence of plasma
lipoproteins on platelet aggregation in a normal male population.
Arteriosclerosis. 1983;3:332–338.
12. Beigel Y, Fuchs J, Snir M, Green P, Lurie Y, Djaldetti M. Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology. J Clin Pharmacol. 1991;31:512–517.[Abstract]
13. Bröijersén A, Eriksson M, Larsson PT, Beck O, Berglund L, Angelin B, Hjemdahl P. Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia. Eur J Clin Invest. 1994;24:488–496.[Medline] [Order article via Infotrieve]
14. Mayer J, Eller T, Brauer P, Solleder EM, Schäfer RM, Keller F, Kochsiek K. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol. 1992;64:196–201.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  F. Gao, L. Linhartova, A. McD. Johnston, and D. R. Thickett Statins and sepsis Br. J. Anaesth., March 1, 2008; 100(3): 288 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Butun, H. Ekmekci, H. Sonmez, C. Gurel, O. Ciftci, T. Ulutin, E. Kokoglu, N. Domanic, and A. Dirican Preliminary Study Showing the Relationship Between Platelet Fibronectin, Sialic Acid, and ADP-induced Aggregation Levels in Coronary Heart Disease Clinical and Applied Thrombosis/Hemostasis, July 1, 2007; 13(3): 308 - 312. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Schafer, D. Fraccarollo, M. Eigenthaler, P. Tas, A. Firnschild, S. Frantz, G. Ertl, and J. Bauersachs Rosuvastatin Reduces Platelet Activation in Heart Failure: Role of NO Bioavailability Arterioscler. Thromb. Vasc. Biol., May 1, 2005; 25(5): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tailor, D. J. Lefer, and D. N. Granger HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1402 - H1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takemoto and J. K. Liao Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Arterioscler. Thromb. Vasc. Biol., November 1, 2001; 21(11): 1712 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Strawn, M. C. Chappell, R. H. Dean, S. Kivlighn, and C. M. Ferrario Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia Circulation, April 4, 2000; 101(13): 1586 - 1593. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||